3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
78
Neoplasm Metastasis
16
Neoplasms
9
Breast Neoplasms, Male
9
Brain Neoplasms
6
Urinary Bladder Neoplasms
5
Ovarian Neoplasms
5
Head and Neck Neoplasms
4
Colorectal Neoplasms
4
Unspecified Adult Solid Tumor, Protocol Specific
3
Prostatic Neoplasms
3
Lung Neoplasms
3
Carcinoma, Squamous Cell
3
Carcinoma, Ovarian Epithelial
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumors
2
Pancreatic Neoplasms
2
Neuroma, Acoustic
2
Neurofibromatosis 2
2
Inflammatory Breast Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Ductal, Breast
2
Salivary Gland Neoplasms
1
Recurrence
1
Prolactinoma
1
Pituitary Neoplasms
1
Patient Compliance
1
Neuroectodermal Tumors, Primitive
1
Interventions
Oxaliplatin
18
Surveys and Questionnaires
15
Fluorouracil
15
Capecitabine
13
Leucovorin
12
Blood Specimen Collection
11
Irinotecan
10
Standard of Care
7
Cisplatin
7
Endoscopic Mucosal Resection
6
atezolizumab
5
Specimen Handling
5
Radiotherapy
5
Educational Status
5
Drug Therapy
5
Docetaxel
5
S 1 (combination)
4
Radiosurgery
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Interviews as Topic
4
Gemcitabine
4
Everolimus
4
Colonoscopy
4
Biopsy
4
Bevacizumab
4
tegafur-gimeracil-oteracil
3
pemigatinib
3
apatinib
3
Remote Patient Monitoring
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gastrointestinal Neoplasms
×
Lapatinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled